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Purpose. The adult myopathy assessment tool (AMAT) is a performance-based battery comprised of functional and endurance
subscales that can be completed in approximately 30 minutes without the use of specialized equipment. The purpose of this study
was to determine the construct validity and internal consistency of the AMAT with a sample of adults with spinal and bulbar
muscular atrophy (SBMA). Methods. AMAT validity was assessed in 56-male participants with genetically confirmed SBMA (mean
age, 53 ± 10 years). The participants completed the AMAT and assessments for disease status, strength, and functional status. Results.
Lower AMAT scores were associated with longer disease duration (𝑟 = −0.29; 𝑃 < 0.03) and lower serum androgen levels (𝑟 = 0.49–
0.59; 𝑃 < 0.001). The AMAT was significantly correlated with strength and functional status (𝑟 = 0.82–0.88; 𝑃 < 0.001). The
domains of the AMAT exhibited good internal consistency (Cronbach’s 𝛼 = 0.77–0.89; 𝑃 < 0.001). Conclusions. The AMAT is a
standardized, performance-based tool that may be used to assess functional limitations and muscle endurance. The AMAT has good
internal consistency, and the construct validity of the AMAT is supported by its significant associations with hormonal, strength,
and functional characteristics of adults with SBMA. This trial is registered with Clinicaltrials.gov identifier NCT00303446.
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1. Introduction
The adult myopathy assessment tool is a standardized,
observed, physical performance test designed to be administered relatively quickly in clinical and research settings
with common clinical equipment and minimal training (see
Table 6 for the list of the AMAT tasks and scoring criteria).
The AMAT consists of a 13-item battery with an ordinal
grading scale for each item and a summated composite functional subscale (range = 0–21), endurance subscale (range =
0–24), and total score (range = 0–45), where lower AMAT
subscale scores and total score indicate decreased physical
performance. The functional and endurance domains that
comprise the AMAT reflect the contribution of impaired
muscle force on functional limitations [1–4] and incorporate
recent findings that physical performance in people with and
without myopathy are also affected by excessive fatigue [5, 6].
The AMAT items include common movements found in
other field tests and clinical assessments [7–13], and have
been adapted to feature integrated timed and criterionbased scoring within discrete measurement domains (i.e.,
functional and endurance AMAT subscales). In addition, the
functional and endurance AMAT subscales are organized to
be congruent with the disability models proposed by both
the Institute of Medicine (IOM) [14] and the World Health
Organization (WHO) [15]. The functional and endurance
subscales were combined for the total AMAT score to imbue
the assessment tool with important analytic advantages
specifically in assessing patients with myopathy. A strict
functional assessment battery based on the attainment of
a transfer or mobility task may exhibit a significant ceiling
effect (more than 15% of subjects attain the maximum score)
if patients have muscle force above what is needed to complete
the task for a single repetition. However, impairments in
these individuals could be revealed during a more demanding
endurance task. In contrast, an endurance battery may display
a significant floor effect (more than 15% of subjects attain
the minimum score) if patients do not have adequate muscle
capacity to meet the criteria for a sustained or repetitive
task [16]. Yet, these same individuals may demonstrate the
requisite strength to complete a single repetition of a less
demanding functional task. Integrating these high and low
demand tasks into the AMAT total score diminishes the
potential floor and ceiling effects of the assessment tool.
Additionally, the AMAT items were sequenced to minimize
the effects of fatigue by avoiding consecutive endurance
tests of a given agonist muscle group. This assessment was
also designed to have clinical utility. Therefore, it may be
completed in 25–35 minutes and requires only common
equipment such as a stopwatch, adjustable height examination table, standard stairs, and a goniometer. Moreover,
the AMAT subscales and total score have been shown
to have high interrater and intrarater reliability (ICC2,1 =
0.95–0.98, 𝑃 < 0.0001) [17].
A sample of individuals with spinal and bulbar muscular
atrophy (SBMA or Kennedy disease), an X-linked degenerative neuromuscular disorder caused by a CAG trinucleotide
repeat expansion in the first exon of the androgen receptor
gene (AR) [18], participated in this study. Briefly, SBMA is
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characterized by muscle fasciculations and cramping, bulbar
weakness that may result in dysphagia and dysarthria [19,
20], and weakness of the proximal and distal muscles that
often leads to impaired mobility and perceptions of excessive
fatigue during upright mobility [19]. This sample was initially
recruited for a larger clinical trial [21] and was used as a model
of neuromuscular disease to help determine selected analytic
properties of the AMAT.
There are few standardized scales available for the assessment of impairments and functional limitations due to
SBMA [19, 25]. Furthermore, self-report assessment tools
may not adequately capture observed functional performance
or physical status [26–28]. The purpose of this study was
to determine the construct validity of the AMAT for adult
participants with SBMA disease. Secondary aims included
determining the internal consistency of the AMAT domains
and the relationship between functional AMAT subscale
items and anatomic regional strength values. Our final aim
was to determine if AMAT cut scores can be defined to reflect
significant differences in strength, activities of daily living
(ADL), timed 2 min walk, or self-reported physical status.

2. Methods
2.1. Participants. Fifty-six subjects (mean age, 53 ± 10 years)
were recruited to the National Institutes of Health (NIH)
Clinical Research Center in Bethesda, MD, for the purpose
of participating in a trial to examine the efficacy and safety
of dutasteride in SBMA [21, 29] (The trial is registered with
Clinicaltrials.gov identifier NCT00303446); all data were
obtained prospectively at the initial screening visit prior
to the administration of dutasteride. Patient demographic
information has been previously presented [29]. The study
was approved by the National Institute of Neurological Disorders and Stroke Institutional Review Board. Signed photograph/recording release forms were obtained from healthy
research volunteers in support of this project, and signed
informed consent was obtained from study participants in
accordance with the Declaration of Helsinki and Federal regulations. Inclusion criteria included: genetically confirmed
SBMA, neurological symptoms of SBMA, ability to walk 100
feet with or without the use of an assistive device, male sex,
and 18 years of age or older. Exclusion criteria included:
female sex, less than 18 years of age, nonambulatory status,
and any joint instability or other medical condition deemed
by the investigators to pose an undue risk to participants
engaging in the performance-based measures associated with
the study.
2.2. Genetic Testing and Serum Androgen Profile. Blood samples were obtained after an overnight fast and processed in a
CLIA-approved laboratory to assess androgen receptor gene
CAG repeat length and serum androgen levels including total
testosterone (TT), free testosterone (FT), and dihydrotestosterone (DHT).
2.3. Quantitative Muscle Strength Testing. Isometric maximal voluntary contraction (MVC) testing via quantitative
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(a)

(b)

Figure 1: Isometric maximal voluntary contraction testing via the quantitative muscle assessment device. (Participant positioning shown for
the: (a) hip extensors and (b) elbow flexors.)

muscle assessment (QMA) was used to measure peak force
of bilateral muscle groups. The muscle groups and testing
positions are listed in Table 7. All QMA tests were performed
on a fixed-dynamometer (AEVERL Medical, LLC, P.O. Box
170, Gainesville, GA 30503) using load cells (Interface, 7401
East Butherus Drive, Scottsdale, AZ 85260) with computerassisted data acquisition. The position of the strap (Figure 1)
was adjusted to avoid contact with the participant and maintain a parallel orientation to the force vector. The dynamometer was calibrated per manufacturer guidelines and reset
to “zero” prior to each MVC attempt to account for the
passive force exerted against the strap. The mean value of the
two MVC attempts was used for summation into a composite
total score and anatomic region score (i.e., upper extremity
and lower extremity).
2.4. Ambulation Status. Ambulation was assessed with the
2-minute walk test [25–30]. The timed 2-minute walk test
has high reproducibility [30, 31] based on ICCs of 0.93.
We administered 3 trials of the 2-minute walk test [32] as
previously described [33], allowing for 2 practice trials before
recording distance walked and gait speed. We compared
the walk distance with the results of Selman and colleagues
[24] to determine the predicted distance for age and gender
matched controls.
2.5. Activities of Daily Living and Self-Reported Health Status.
ADL assessment was modified [21, 29] from the ADL survey
from the Friedreich ataxia rating scale (FARS) [34] by
substituting a question about bladder control for one regarding difficulty with handwriting. While this questionnaire
is validated for individuals with Friedreich ataxia [35], the
ADL items reflect many of the limitations experienced by
individuals with SBMA (i.e., walking, falling, swallowing,
speech, dressing, personal hygiene, food handling and utensil
use, and sitting position quality). The ADL assessment scores
were inverted for statistical analysis, producing an ordinal
0–4 item scale (0 = maximum limitation; 4 = unaffected)
and a summated composite total score of 36 (range = 0–36)
with higher scores indicating increased levels of functioning.

“Walking” and “falling” were individual ADL assessment
items selected for additional analyses to better understand
their relationship with AMAT performance.
Modules from the Medical Outcomes Study 36-item
short form (version 2) questionnaire (SF-36v2) were used
to obtain self-reported information on physical functioning
and mental status. The SF-36v2 is a 36-item, 4-week recall
health-related quality of life assessment that has been used
in multiple disorders and can be condensed into 2 summary
measures: the physical component summary (PCS) and the
mental component summary (MCS) [36, 37]. Using the
SAS code provided by QualityMetric Inc., raw scores were
converted into normative-based scores with a mean score of
50 (standard deviation, ±10). The scoring algorithms for all
SF-36v2 scales and summaries are gender- and age-matched
and facilitate simple and valid comparisons between groups
[38, 39].
2.6. Administration of the AMAT. A single physician with
five years of experience with the AMAT administered the
observed, physical performance test to the study participants.
The test administrator issued instructions along with task
demonstration for each AMAT activity before the participants attempted a given task. In addition, all participants were
informed of the criteria to end each task (see Table 6) and
the test administrator provided “standby” guarding to ensure
participant safety during tasks requiring upright mobility.
The participants were allowed a single attempt at completing
each AMAT task; however, additional task attempts were
allowed in the event of a procedural error during testing.
The AMAT was initiated without warm up or preparatory
activities and performed a minimum of 4 hours apart from
the QMA and 2-minute walk test to avoid the negative impact
of fatigue incurred from prior activity.
2.7. Data Analysis. Descriptive statistics were used to depict
participant characteristics and all outcome measures. All
data are expressed as means and standard deviations except
individual AMAT item scores. The ordinal item scores are
shown as median values and the interquartile range (IQR).
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Additionally, only the data distribution of the MCS and
the functional subscale of the AMAT exhibited a significant
departure from normality. Therefore, the data associated with
these measures were the only variables requiring the use
of nonparametric statistics [40]. In this study, the construct
validity of the AMAT was based on the strength of its
association with outcome measures that influence or reflect
functional limitations and submaximal muscle endurance:
androgen and genetic markers, muscle strength, timed 2minute walk, ADL, and self-reported physical status. Construct validity is the extent that inferences may be made from
the operational definitions within an assessment tool to the
larger theory or concept of interest [40, 41]. Self-reported
physical status, via the PCS, was expected to correlate with
the AMAT and was used with the other outcome measures
to assess construct validity. In contrast, self-reported mental
status via the MCS was not expected to correlate with
the AMAT and was used to establish divergent validity.
Divergent validity of a given assessment tool is supported
by a test outcome that lacks a significant association with
variables presumed to measure different domains and should
be independent of the outcome or construct of interest [41].
Pearson product-moment correlation coefficients
(PMCC, 𝑟) and Spearman’s correlation coefficients (Spearman’s rho, 𝜌) were used to assess the association between
variables, and the strength of the association among the
variables was based on Munro’s criteria [42]. Stepwise
multiple linear regression analysis was used to determine
the association between variables while accounting for the
covariation among disease duration, CAG repeat length, TT,
FT, and DHT [43]. All linear regression analyses and correlation coefficients involving QMA strength data included
the values scaled to body weight (kg of MVC force/kg of
body weight, resulting in a unitless value). This method
of scaling strength data facilitated our analysis of the
relationship between muscle strength and the functional
tasks featured in the AMAT that involve the movement of
body weight [44, 45]. QMA values were also expressed as a
composite score (total QMA) and anatomic region scores
(i.e., upper extremity and lower extremity QMA). Normativebased reference strength values, obtained from the National
Isometric Muscle Strength (NIMS) Database Consortium
[22] and Andrews and associates [23], were used for
comparison with the SBMA group.
Low, moderate, and high levels of physical performance
were determined by organizing subgroups of subjects based
on cut scores derived from the AMAT total score tertiles.
An analysis of variance (ANOVA) was used to discriminate
among subjects with higher and lower levels of impairment
[43]. The Kruskal Wallis test with Mann Whitney 𝑈 post
hoc tests were used for ADL falling and walking items
since they involve ordinal data. Internal consistency of the
functional and endurance AMAT subscales was assessed
using Cronbach’s alpha (𝛼). These AMAT subscales represent
related, but heterogeneous, aspects of physical functioning.
Therefore internal consistency was evaluated for both AMAT
subscales. Internal consistency is based on the pairwise correlations among the items within a subscale used to represent
a given construct [40]. An a priori decision was made to
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consider Cronbach’s 𝛼 values of >0.70 as acceptable internal consistency of an AMAT subscale. In contrast, values
exceeding 0.95 were considered indicative of a subscale with
excessive item redundancy. Intra-item correlations were also
calculated and coefficient values exceeding 0.85 indicated a
redundant subscale item. The alpha level (two-tailed) was
set at 0.05, and the statistical analyses were performed using
SAS 9.1.3 (SAS Institute, Inc., Cary, NC), SUDAAN 9.0 for
Windows (Research Triangle Institute Inc., Cary, NC), and
SPSS statistical software version 10.0 for Windows (SPSS Inc.,
Street 233 S. Wacker Drive, Chicago, IL 60606).

3. Results
3.1. Participant Demographics and Disease Characteristics.
The mean age of study sample at the time of trial participation
was 53 (±10) years with a mean AR gene repeat length of
47 CAGs (range = 41–53). Detailed patient demographic
information and serum androgen levels have been previously
presented [29].
The participants with SBMA had diminished strength
levels in comparison to the normative data. The MVC forces
represented by the scaled total QMA score, scaled upper
extremity (UE) QMA score, and scaled lower extremity (LE)
QMA score were 42% to 65% of the reference values (Table 1).
The mean distance travelled during the timed 2-minute walk
was 109 ± 50 m for the participants corresponding to a mean
velocity of 0.9 m/s (Table 1). Twenty-two of the 56 participants (39%) opted to use assistive devices (e.g., canes, walkers,
or ankle-foot orthoses). These participants attained a mean
distance of 66 ± 23 m with a mean speed of 0.55 m/s, whereas
the individuals who did not use assistive devices achieved a
mean distance of 136 ± 44 m (𝑛 = 34) with a mean speed of
1.13 m/s.
The ADL assessment score indicated that the participants
experienced difficulties with physical functioning; the mean
ADL assessment score was 25.9 ± 5.0 (range 15.0–35.3),
representing 72% of the maximum attainable score. This is
in agreement with the self-reported physical status in which
the subjects had a mean PCS score of 34.3 ± 11.0 (16.0–57.8)
which is 68% of the national age-matched normative data for
men (35–74 years of age). In contrast, the self-reported mental
status was noted by MCS mean scores of 52.2±11.6 (14.2–67.2)
which is 102% of normative values [38, 39].
3.2. The AMAT Subscale Scores and Total Score. Observed
physical functioning, as measured with the AMAT, also
revealed impaired performance of the participants. The mean
total AMAT score was 29.2 ± 10.3 (i.e., 65% of the maximum
AMAT total score) and no significant floor or ceiling effects
were found in the AMAT total scores [16]. Of the 56 subjects,
no one attained the low score of 0, and 2 participants
achieved the maximum score of 45. In addition, slightly
greater deficits were noted in the endurance AMAT subscale
(60% of the maximum score) in comparison to the functional
AMAT subscale (70% of the maximum score; Table 1). A
range of performance ability was observed in both the functional and endurance AMAT subscales. Median item scores
ranged from 1.0 to 3.0 for functional AMAT subscale items
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Table 1: Physical performance assessments in patients with SBMA.
Quantitative muscle assessment (kg)
Upper extremity composite
Lower extremity composite
Total force
Adult Myopathy Assessment Tool
Endurance score (range = 0–24, 24 = max score)
Functional score (range = 0–21, 21 = max score)
Total score (range = 0–45, 45 = max score)
Timed 2-minute walk (m)
Distance walked

SBMA mean ± SD (range)

Percentage of reference values†

66 ± 25 (18–140)
98 ± 41 (28–231)
164 ± 63 (63–372)

42%
65%
55%

14.5 ± 5.3 (4–24)
14.7 ± 5.4 (2–21)
29.2 ± 10.3 (9–45)

60%
70%
65%

109 ± 50 (15–208)

51%

†

Normative QMA values obtained from published reference values [22, 23]; AMAT results expressed as a percentage of the maximum attainable score; timed
2 minute walk results compared with published age and gender matched normal reference values [24].
Abbreviations: SBMA: spinal bulbar muscular atrophy; kg: kilograms; m: meters.

Table 2: AMAT item scores for patients with SBMA.
Functional AMAT subscale items (range = 0–3)
Supine to prone
Modified push-up
Sit-up
Supine to sit
Arm raise
Sit to stand
Step-up
Endurance AMAT subscale items (range = 0–4)
Sustained head elevation
Repeated modified push-ups
Sustained arm raise
Sustained hip flexion
Sustained knee extension
Repeated heel raises

Median score

IQR

3.0
3.0
1.0
3.0
3.0
2.0
2.0

2.0–3.0
2.0–3.0
0.0–2.0
2.0–3.0
2.0–3.0
1.0–3.0
1.0–3.0

3.0
1.0
3.0
4.0
4.0
0.0

2.0–4.0
0.0–2.0
1.3–4.0
2.0–4.0
4.0–4.0
0.0–1.0

Abbreviations: SBMA: spinal bulbar muscular atrophy; IQR: interquartile range; AMAT: Adult Myopathy Assessment Tool.

(item scale = 0–3) with the sit-up, sit to stand, and step-up
tasks being the most difficult to perform. Median item scores
varied across the full range of 0 to 4 for endurance AMAT
subscale items (item scale = 0–4), with the repeated heel raises
and repeated modified push-ups scoring the lowest (Table 2).
3.3. Outcome Variables Associated with the AMAT Total
Score. The serum androgen levels had a moderate degree of
association with the AMAT (𝑟 = 0.49–0.62; 𝑃 < 0.001).
The AMAT was significantly associated with CAG repeat
length (𝑡 = −3.95; 𝑃 < 0.001) when the multiple linear
regression model corrected for age at evaluation and total
testosterone as covariates. There was a stronger relationship
between the AMAT and outcome measures related to physical
performance. The total QMA score, timed 2-minute walk
distance, and ADL assessment score all showed a high degree
of association with the AMAT (𝑟 = 0.82–0.91; 𝑃 < 0.0001).
The self-reported physical status, as estimated by the PCS
score, also correlated well with AMAT (𝑟 = 0.62; 𝑃 < 0.0001)
and, as hypothesized, the self-reported mental status via the

MCS did not (𝑟 = 0.13; 𝑃 = 0.355). Correlations between the
AMAT total score and the outcome variables are summarized
in Table 3.
3.4. Internal Consistency of the AMAT Subscales. The internal
consistency of both AMAT subscales was acceptable based
on the criteria established by Munro [42]. However, the
internal consistency of the AMAT domains was stronger in
the functional AMAT subscale (Cronbach’s 𝛼 = 0.89) than in
the endurance AMAT subscale (Cronbach’s 𝛼 = 0.77). Intraitem associations of the AMAT subscales did not suggest item
redundancy, as none of the correlation coefficients exceeded
0.85. The inter-item Spearman’s 𝜌 ranged from 0.39 to 0.74
for the functional AMAT subscale and 0.11 to 0.73 for the
endurance AMAT subscale.
3.5. Strength-Function Relationships. Association between
the functional AMAT subscale items and the QMA values
was used to characterize strength-function relationships
(Table 4). The total QMA, UE QMA, and LE QMA scores
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Table 3: Pearson’s correlation coefficients of the AMAT total score and SBMA outcome measures and phenotypic variables.
𝑃 value
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
<0.0001
0.0002
0.002
0.03
0.355

AMAT Total Score
0.91
0.85
0.82
0.82
0.62
0.51
0.49
−0.40
−0.29
0.13

Scaled total QMA
Timed 2-minute walk
ADL assessment
Physical component summary§
Total testosterone
Dihydrotestosterone
Free testosterone
Age
Disease duration†
Mental component summary§
§

Self-report of physical and mental status obtained from the physical component summary and mental component summary of the Medical Outcomes Study
36-item short form, version 2.
†
Disease duration is defined as time from genetic diagnosis to study initial evaluation.
Abbreviations: SBMA: spinal bulbar muscular atrophy; AMAT: Adult Myopathy Assessment Tool; QMA: Quantitative Muscle Assessment; ADL: activities of
daily living.

Table 4: Spearman’s correlation coefficients of the scaled QMA strength values and AMAT Functional subscale items.

UE QMA
LE QMA
TOTAL QMA

Supine to prone
0.379
0.524
0.487

Push-up
0.616
0.559
0.628

Sit-up
0.623
0.756
0.745

Supine to sit
0.570
0.724
0.687

Arm raise
0.588
0.471
0.553

Sit to stand
0.614
0.764
0.739

Step-up
0.637
0.813
0.777

Note: all 𝑃 values are <0.001, except UE QMA and supine to prone, 𝑃 = 0.004; all QMA values are scaled to body weight.
Abbreviations: UE: upper extremity; LE: lower extremity; AMAT: Adult Myopathy Assessment Tool; QMA: quantitative muscle assessment.

were significantly correlated with all of the functional tasks.
The anatomic region QMA scores were more strongly associated with the functional tasks than the total QMA score,
with the exception of the modified push-up. The UE QMA
score had the highest degree of association with arm raise (𝜌 =
0.59; 𝑃 < 0.001). In comparison, the LE QMA score had the
highest degree of association with the supine to prone, sit-up,
supine to sit, sit to stand, and the step-up tasks (𝜌 = 0.72–0.81;
𝑃 < 0.001).
3.6. AMAT Cut Scores. Total AMAT score tertiles led to cut
scores that separate the sample into low ≤ 24, moderate 25–
34, and high ≥ 35 functioning groups. Significant differences
were found among all 3 groups for the total QMA, timed
2-minute walk, total ADL, ADL falling, and ADL walking
assessment scores (𝑃 < 0.001 for all main effects). Post
hoc differences for ADL falling and walking were significant
among all three groups; 𝑃 < 0.001 in all comparisons except
between the moderate and high functioning groups (𝑃 =
0.023). The low and high AMAT cut score groups showed
significant differences in FT (𝑃 < 0.001), TT (𝑃 < 0.001), and
DHT (𝑃 = 0.012), but not CAG repeat length (𝑃 = 0.41). In
addition, the low and high and moderate and high AMAT cut
score groups had significantly different physical status selfreport scores (𝑃 < 0.001). All comparisons of the AMAT
cut scores and outcome values in the functional domain are
summarized in Table 5.

4. Discussion
4.1. Construct Validity of the AMAT. The findings of this
investigation support the construct validity and internal
consistency of the AMAT in participants with SBMA disease.
Dependent measures obtained to characterize disease status
and validate the AMAT included serum androgen levels, AR
gene CAG trinucleotide repeat length, QMA scores, timed 2minute walk, ADL assessment, and self-reported physical and
mental status. Androgen levels are linked to the maintenance
of muscle mass and strength [46], which in turn, leads
to improved physical functioning [3, 47]. The relationship
between the higher androgen levels and better functional performance was reflected in the significant correlation between
the AMAT score and TT, FT, and DHT in the participants.
We found a significant relationship between AR gene CAG
trinucleotide repeat length and the AMAT total score, when
accounting for the covariation of age at evaluation and
TT. This finding supports other reports that CAG repeat
length affects phenotypic measures of disease status [29, 48].
Additionally, previous work from our group [21] showed that
there was an inverse correlation between CAG repeat length
and QMA values scaled to body weight (𝑃 = 0.04).
The participants had significant impairment based on
strength levels and walking distances that were approximately
half of the normal adult reference values [24]. Also, the
ADL assessment scores of the participants (25.9 ± 5.0; maximum attainable score = 36) were diminished, but similar to
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Table 5: AMAT cut scores. Use of AMAT cut scores to discriminate among low, moderate, and high levels of performance across several ICF
domains of function.
AMAT
Functional level
1-low
2-moderate
3-high
ANOVA

QMA
Score
0–24
25–34
35–45

𝑁
19
18
19

2.48 (±0.70)
3.27 (±0.77)
5.48 (±1.26)
52.9

Tukey’s HSD
1-2
2-3
1–3

0.02
<0.001
<0.001

2MWT (m)

PCS

Mean (SD)
58.7 (±24.0)
27.3 (±7.3)
103.1 (±27.7)
31.5 (±8.3)
163.7 (±24.3)
43.9 (±9.81)
𝐹 value (all 𝑃 values, <0.001)
60.1
18.3
𝑃 values
0.003
0.341
<0.001
<0.001
<0.001
<0.001

ADL
21.0 (±3.0)
26.0 (±3.1)
30.7 (±3.4)
44.7
<0.001
<0.001
<0.001

Note: Cut scores are based on the tertiles of the AMAT total score. QMA values have been scaled to body weight.
Abbreviations: AMAT: Adult Myopathy Assessment Tool; ICF: International Classification of Functioning; QMA: quantitative muscle assessment; 2MWT:
timed 2 minute walk; (m) meters; PCS: Physical Component Summary (obtained from the Medical Outcomes Study 36-Item Short Form, Version 2); ADL:
activities of daily living; (SD) standard deviation; ANOVA: analysis of variance; Tukey’s HSD: Tukey’s Honestly Significant Difference.

the clinical measures reported in other studies [49, 50]. The
mean AMAT total score of 29.2 (±10.3; maximum attainable
score = 45) reflects the decreased physical performance of
the participants and is consistent with the findings regarding
impaired muscle strength, ADL assessment, and self-reported
physical status.
4.2. AMAT Subscale and Item Assessment. The AMAT subscales and items vary in their level of difficulty. Task difficulty
is based on the proportion of body weight being moved and
the distance traversed. However, task performance may be
influenced by patterns of muscle weakness in people with
neuromuscular disease. Based on the median item scores,
supine to prone, modified push-up, supine to sit, and arm
raise were the least demanding tasks of the functional AMAT
subscale, while the sit-up, sit to stand, and step-up tasks posed
the largest challenge to the participants. Sit to stand and
ascending a step were expected to be challenging tasks due
to the requirement to move one’s total body weight and the
reports of difficulty with these tasks in other cohorts. However, the data suggesting that the sit-up was the most difficult
task was unexpected and has not been previously described
in SBMA. Trunk weakness is a notable finding that has been
observed in myopathies such as polymyositis and dermatomyositis [51]. Muscle groups of the extremities are typically
more readily tested with dynamometry than trunk muscles,
so the trunk musculature is typically omitted from objective
strength assessment studies. Nevertheless, the observed difficulty with the sit-up task suggests that the trunk muscles may
merit standardized objective strength assessment.
Sustained knee extension and hip flexion were the least
difficult tasks of the endurance AMAT subscale, but even
these tasks detected impairments in our sample (13 and
25 participants, resp., failed to reach the maximum score).
Repeated heel raises and modified push-ups were clearly the
most difficult tasks of the endurance AMAT subscale. The
repeated heel raise task performance revealed the extent of
distal weakness in the participants. The ankle plantar flexors
can generate a large magnitude of force based on the lever

type of the ankle joint and the muscle architecture of the
gastrocnemius [52]. Despite these physiologic advantages,
39/56 subjects (70%) were unable to perform a single limb
heel raise. The diminished performance of the participants
for the repeated push-up task was of interest given the high
scores attained on the single repetition version of this task in
the functional AMAT subscale. The decreased performance
of the repeated version of the push-up item may indicate
sufficient strength to complete the task, but inadequate muscle endurance capacity to sustain task performance. Indeed,
investigators have cited the need for endurance tests in
addition to single repetition functional tasks alone to capture
this important aspect of physical performance in persons
with myopathy [6]. Repeated movements such as heel raises
may be noted by performance deficiencies due to diminished
strength and anaerobic capacity at ancillary muscle groups
that contribute to stability during tasks with substantial
multijoint involvement [53]. Additionally, SBMA is notable
for being a lower motor neuron disease with significant
muscle tissue abnormalities. Signs of significant muscle fiber
damage such as elevated levels of serum creatine kinase often
precede stereotypic SBMA clinical symptoms [54]. Also, muscle tissue in those with SBMA is distinguished by aberrant
features such as fiber type grouping and centrally located
nuclei which reflect characteristics of both neurogenic and
myogenic pathology [55]. These morphological and histological abnormalities would contribute to the physical deficits
observed in our sample during AMAT testing.
4.3. Characterizing the Strength-Function Relationship Based
on AMAT Performance. Construct validity of the AMAT
was also supported by the observed strength-function relationships. For example, the UE and LE QMA scores were
more strongly associated with the functional AMAT subscale
items than the total QMA score. Specificity of the composite
regional strength scores moderately improved the observed
strength-function relationships for nearly every task. Interestingly, LE QMA was strongly correlated with the sit-up task.
However, a stronger correlation may have been attained with

0 >10 seconds to attempt
transfer or unable
1 completion in >6
seconds <10 seconds or
rolls without freeing
dependent arm
2 completion in >3
seconds ≤6 seconds
3 completion in ≤3
seconds
0 unable to do
1 partial elbow extension;
sternum in partial
contact with table
2 partial elbow extension;
sternum NOT in
contact with table
3 full elbow extension
achieved

Supine to prone: “Roll onto your stomach without
stopping and place your arms at your side.” Patient
begins in supine with arms at side; test ends when
patient is prone with arms at side.

Modified push-up: “Perform a push-up, ending with
your elbows as straight as possible; your knees will
touch the table during the movement.” Patient begins
with hands facing forward on table with arm in 0
degrees abduction.

1

2

3

†

0 <5 seconds or unable
1 5–30 seconds
2 31–60 seconds
3 61–90 seconds
4 >90 seconds

Scoring

Head elevation endurance: “Raise your head off of the
table.” Patient in supine; patient flexes head and neck
forward and attempts to maintain self-selected position;
test ends when occiput touches table.

Item instructions and descriptions

Table 6: The adult myopathy assessment tool (AMAT).
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0 unable to do
1 scapulae and T7 vertebra
not in contact with table
(rectus phase) with counter
balance
2 L1 vertebra not in
contact with table:
completion of full sit-up
(hip flexor phase) with
counter balance
3 completion of full sit-up
without
counter balance

0 ≥12 seconds to attempt
transfer or unable
1 completion in >7 and
<12 seconds
2 completion in >4 and ≤7
seconds
3 completion in ≤4
seconds

Sit-up: “Perform a sit-up.” Patient begins from supine
position with knees fully extended and with hands on
thighs or across abdomen; tester applies counter
balance at distal lower extremities for grades 0–2.

Supine to sit: “Move to a sitting position at the edge of
the table as quickly as you can.” Patient begins from
supine position, legs straight, and arms at side. Test
ends when feet touch the floor and torso is vertical.

5

6

0 unable to do
1–10 repetitions
11–20 repetitions
21–30 repetitions
31–40 repetitions

4

1
2
3
4

Scoring

Table 6: Continued.

†
Repeated modified push-up: “Perform as many
push-ups as you can, ending with arms straight, in 2
minutes; your upper chest should touch the table with
each repetition.” Patient begins with hands on table and
shoulders in 0 degrees abduction; self-selected pace;
test ends if cueing for faulty technique occurs on 2
consecutive attempts; faulty attempts are not counted.

Item instructions and descriptions
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Arm raise: “Raise both hands as high as you can above
your head with the elbows straight.” Complete within
available PROM; apply grade to weakest upper
extremity if asymmetry is present.

0 unable to do or <5
seconds
1 5–30 seconds
2 31–60 seconds
3 61–90 seconds
4 >90 seconds

0 unable to do
1 completes transfer with
two or more
extremities in contact with
the exam table or thigh
2 completes transfer with
one extremity
in contact with the exam
table or thigh
3 completes transfer
without contact
of any extremity with the
exam table or thigh

Sit to stand: “Stand up with as little arm support as
possible.” Patient seated on exam table with edge
bisecting thigh length, trunk erect, lower legs vertical,
and knees at 90 degrees measured via goniometer;
contact between posterior aspect of the legs and the
table is not allowed.

8

9

†

0 unable to raise arms to
level of acromioclavicular
joint
1 hands raised between
acromioclavicular joint and
top of head
2 hands raised above top
of head without full
elbow extension
3 hands raised above top
of head with full
elbow extension

Arm raise endurance: “Raise both hands forward
(shoulder flexion) to eye level with elbows straight.”
Trunk upright without hyperextension and both feet
flat on floor; end test if shoulder flexion drops below 90
degrees; apply grade to weakest upper extremity if
asymmetry is present.

7

Scoring

Table 6: Continued.

Item instructions and descriptions

10
Rehabilitation Research and Practice

0 unable to do
1 1–7 repetitions
2 8–15 repetitions
3 16–23 repetitions
4 24–30 repetitions

†
Repeated heel rise: “While standing on your
dominant leg only, raise your heel off of the ground.”
No shoes; self-selected pace; test ends when 5th
metatarsal base or midfoot does not fully rise from the
floor; test ends if cueing for faulty technique occurs on
2 consecutive attempts; faulty attempts are not counted;
knees remain as straight as possible with no additional
flexion during attempts; minimal external support may
be provided by a wall; 2 min or 30 repetition limit.

11

12

†

0 unable to do or <5
seconds
1 5–30 seconds
2 31–60 seconds
3 61–90 seconds
4 >90 seconds

0 unable to do or <5
seconds
1 5–30 seconds
2 31–60 seconds
3 61–90 seconds
4 >90 seconds

Scoring

Table 6: Continued.

Knee extension endurance: “Hold your knee as
straight as possible on your dominant side.” No shoes;
nondominant foot on floor; trunk upright with thigh
fully supported on table; test ends when the foot
contacts the floor; full available PROM.

10

Hip flexion endurance: “Raise and hold your knee in
the air on your dominant side.” Seated with hips and
knees at ninety degrees; no shoes; nondominant foot on
floor; trunk upright with edge of table bisecting thigh
length; upper extremity support on table allowed; knee
height is based on the mid-PROM; test ends when foot
contacts the floor.

†

Item instructions and descriptions
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0 unable to do
1 uses two upper
extremities
2 uses one upper
extremity
3 completes without upper
extremity use

Step-up: “Place your dominant leg onto the 7-inch step,
step forward with as little arm support as possible, and
bring the opposite foot onto the step.” Stable upper
extremity support should be available for both arms.

Denotes AMAT endurance subscale items.
General instructions: all AMAT items should be performed in order 1 through 13 with at least one-minute rest period after each item. Rest periods exceeding one minute are dictated by the transition time required
to set up proceeding AMAT tasks. Test ending criteria should be provided prior to each task attempt. Standby assistance is required for all items requiring upright mobility. Duration for all timed tasks should be
recorded. Required items: stopwatch, examination table, goniometer or inclinometer, and stairs with a handrail.
Scoring: Each AMAT item is scored immediately after the task attempt is completed. The AMAT functional subscale (range = 0–21), AMAT endurance subscale (range = 0–24), and AMAT total score (range = 0–45)
are calculated after test administration.
Interpretation: AMAT functional level (categorical ranks are based on the AMAT total score)
1-low 0–24
2-moderate 25–34
3-high 35–45
PROM: passive range of motion.

†

13

Scoring

Table 6: Continued.

Item instructions and descriptions

12
Rehabilitation Research and Practice

Rehabilitation Research and Practice

13

Table 7: Quantitative assessment of peak muscle force. The tested muscle groups, subject testing position, and orientation of the dynamometer
strap are listed for the quantitative assessment of maximum isometric force C using a fixed dynamometry load cell£ .
Muscle group
Upper extremity
Lateral pinch
Hand grip
Wrist flexors
Elbow flexors
Elbow extensors
Shoulder abductors
Lower extremity
Ankle dorsiflexors
Knee extensors
Hip flexors
Hip extensors
Hip abductors

Patient position

Strap position

Seated; elbow at 90∘ ; midrange supination/pronation
Seated; elbow at 90∘ ; midrange supination/pronation
Seated; elbow at 90∘ ; midrange supination/pronation
Supine; elbow at 90∘ ; midrange supination/pronation
Supine; elbow at 90∘ ; midrange supination/pronation
Supine; shoulder and elbow at 90∘
Supine; ankle at 90∘
Seated; hip and knee at 90∘
Supine; hip and knee at 90∘
Supine; hip and knee at 90∘
Seated; hip and knee at 90∘

None; pinch dynamometer
None; hand grip dynamometer
Ventral metacarpals with second stabilizing strap at
dorsal proximal wrist
Radial distal forearm proximal to wrist
Ulnar distal forearm proximal to wrist
Lateral distal arm proximal to elbow
Around dorsal metatarsals
Around ankle and proximal to malleolus
Anterior distal femur and proximal to patella
Posterior distal femur
Lateral distal femur

C AEVERL Medical, LLC P.O. Box 170 Gainesville, GA 30503.
Interface, 7401 East Butherus Drive, Scottsdale, AZ 85260.

£

a specific measure of trunk strength, which was not included
in this study. In addition, it is unclear why the total QMA
score was more strongly correlated to the modified pushup task than was the UE QMA score. The muscle groups
included in the composite UE QMA score did not include
the horizontal adductors of the humerus, and the addition of
this group may have improved this relationship. Our results
also confirm the findings from other investigators regarding
the positive relationship between task difficulty and strength
[56]. Among the most difficult AMAT functional tasks were
sit to stand and step-up (median score = 2.0). The highest
strength-function correlations we observed involved tasks
with a clear LE-bias ranging from 0.76 to 0.81. In contrast, the
correlations for the UE-biased tasks ranged from 0.59 to 0.62.
The large magnitude of association between muscle strength
and LE-biased tasks observed in this study is similar to the
findings of other studies of participants with neuromuscular
disease [57].
4.4. Internal Consistency of the AMAT. While both AMAT
subscales demonstrated good internal consistency, the functional subscale outperformed the endurance subscale. Frank
muscle weakness can confound attempts to measure muscle
endurance. Repeated or sustained tasks are designed to measure muscle endurance, but they also demand the requisite
strength to attain the testing position. The distal weakness
exhibited by the participants rendered the repeated heel raise
test, an endurance AMAT subscale item, a de facto functional
test contingent on strength. Therefore, severe neuromuscular
disease that yields specific muscle groups with frank weakness would cause a series of muscle endurance tests to be
divergent in their results, thus lowering the intercorrelation
of the test items.
4.5. Utility of the AMAT: Cut Scores and Functional Performance Categories. The ability to derive meaning from
the scores of a given outcome measure is a key arbiter of

assessment tool utility. The determination of AMAT cut
scores revealed significant categorical differences in physical
performance. These observed differences included strength,
walking, total ADL, ADL falling, and self-reported physical
status. Participants categorized as having a “high” level of
functional performance were at least twice as strong as those
categorized as having a “low” level of functional performance.
Similarly, walking distance was nearly three times farther
in participants demonstrating a higher level of functional
performance in comparison to people in the lowest functional
category. This sharp contrast in physical functioning suggests
that the AMAT cut scores may reveal clinically meaningful
differences among the categorical groups. Clinicians may
find that AMAT cut scores augment their ability to determine when additional rehabilitative interventions or more
detailed assessments are indicated for patients with declining
physical status. Moreover, AMAT cut scores may be used
by researchers as part of the inclusion or exclusion criteria
of a therapeutic trial, to aid group assignment based on
the severity of physical impairment or provide a criterion
for clinically meaningful improvement or worsening when
participant AMAT scores shift in categorical rank. Despite
the clear functional distinctions observed in the categorical
grouping of our sample, additional study will be needed to
better understand how the AMAT cut scores identified in
this study apply to other samples and patient populations.
Myopathy is a broad category of pathology that encompasses
multiple neuromuscular disorders and myogenic diseases.
Therefore, the AMAT was not created for the express purpose
of assessing individuals with SBMA. Our preliminary data
from previous and ongoing clinical studies suggest that the
AMAT is a robust measure of physical performance in people
with inclusion body myositis and that clinicians exhibit a
high degree of reliability scoring AMAT performances by
individuals with idiopathic inflammatory myopathies [17].
This performance-based test is intended for use by rehabilitation practitioners such as physicians, therapists, and
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nurses and may be conducted in physical therapy clinics,
outpatient medical facilities, and rehabilitation units within
a hospital setting. The emerging analytic properties of the
AMAT, including the ability to monitor patient status over
time and observe meaningful shifts in the AMAT functional
level (i.e., low, moderate, and high), are valuable features of
a test designed to characterize the physical performance of
people with chronic degenerative conditions. Our findings in
support of the construct validity and internal consistency of
the AMAT complement our previous observations regarding
the ability of the AMAT to assess disease progression.
Fernández-Rhodes et al. [29] examined the efficacy and
safety of dutasteride in characterizing disease progression
over a 24-month period in the placebo-control SBMA group
with a variety of secondary measures of impairment level
and physical status. Motor unit number estimation, median
compound muscle action potentials, and total QMA score
detected an annual rate of decline from 1.6% to 2.3%. In
contrast, the AMAT and the PCS score showed an annual
decline of 4.5% and 5.2%, respectively. However, of these
two measures, the AMAT was better at detecting a decline
in physical status (𝑧 = 0.68, 𝑃 = 0.004 versus 𝑧 = 0.43,
𝑃 = 0.054). Therefore, the AMAT may have utility in future
clinical trials based on its favorable “signal-to-noise” ratio.

Rehabilitation Research and Practice
normative reference data, need to be explored to fully
understand the clinical and research utility of the AMAT.

6. Conclusions
The AMAT is a standardized, performance-based tool that
assesses functional limitations and muscle endurance in
adults with myopathy. Our findings suggest that the AMAT
has excellent construct validity and good internal consistency
for adults with SBMA based on its significant associations
with strength, objective and subjective physical performance
measures, and self-reported physical status. The utility of
the AMAT is further supported through the use of cut
scores to characterize physical status based on low, moderate,
or high levels of performance. These findings support the
use of the AMAT as both a clinical assessment tool and
outcome measure in future clinical trials of SBMA and merits
further study in other adult-onset neuromuscular disease
populations.
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5. Limitations
Although the findings support the construct validity and
internal consistency of the AMAT, this study had limitations.
Our outcome measures did not include a direct measure of
muscle endurance. While the capacity of muscles to exert sustained or repeated submaximal forces is consistent with the
requirements of ADL performance and mobility, validation of
the endurance AMAT subscale would have been improved by
comparisons with an impairment-level measure of anaerobic
endurance. The AMAT and other physical performance tests
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muscle function and various nonmusculoskeletal features of
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purpose and validity of the AMAT benefits from the integrity
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to address the consequences of neuromuscular disease that
go beyond physical performance and mobility. Additionally,
the cut scores used to categorize participants into AMAT
functional levels in this study yielded statistically significant
distinctions among the 3 subgroups. However, cut scores
based on percentiles are dependent on the distribution of
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markers of disablement. A successful implementation of this
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